Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Jan. 3, 2020

Trial to evaluate Trevena's TRV-734 for opioid use disorder

Dec. 24, 2019

Embera NeuroTherapeutics receives funding to advance EMB-001 into phase II studies

Dec. 20, 2019

Indivior selects CRO to conduct phase I study of INDV-2000

Dec. 10, 2019

Adamis Pharmaceuticals receives a complete response letter regarding Zimhi

Nov. 26, 2019

Binging brains give themselves away

Nov. 26, 2019

Diabetes drug eases nicotine withdrawal

Nov. 14, 2019

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

Oct. 24, 2019

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Oct. 18, 2019

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Oct. 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...